Eli Lilly Q2 FY26 EPS rises 26% to $7.94; revenue increases 48% to $23 billion
PUBT · 1d ago
Share
Listen to the news
- Eli Lilly Q2 2026 revenue rose 48% to USD 23 billion, while GAAP EPS climbed 26% to USD 7.94.
- GAAP net income increased 25% to USD 7.1 billion, with results including USD 3.03 per share of acquired IPR&D charges.
- Non-GAAP EPS increased 33% to USD 8.38, despite USD 3.03 per share of acquired IPR&D charges.
- Raised 2026 revenue guidance to USD 85-87 billion; updated non-GAAP EPS outlook to USD 35.5-36.5.
- CEO David Ricks cited momentum, new manufacturing capacity coming online, pipeline additions, and plans to file retatrutide obesity BLA in Q1 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608050645PR_NEWS_USPR_____DE19455) on August 05, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending